PureTech Health
PRTC · Main Market · Health Care · mcap £262m · 111.0p
PureTech founds and part-owns biotech companies, developing some programmes itself before spinning them into separate 'Founded Entities' funded by outside investors. It earns returns through equity stakes, milestones and royalties.
Financials · LTM to 30 Jun 26
Source: results 22 Sep 26 ↗
- Revenue
- £4.8m
- Operating profit
- −£76.7m
- Net income
- £1.1m
- Free cash flow
- −£64.9m
- Net cash
- £87.4m
- Market cap
- £272m
- EV / EBIT
- –
- FCF yield
- −23.9%
- Price / book
- 1.0×
Latest half-year · H1 26 vs H1 25
results 22 Sep 26 ↗
- Revenue
- £2.6m +85%
- Operating profit
- −£38.9m prior −£37.0m
- Net income
- £50.0m prior −£34.4m
- Cash from operations
- −£33.0m prior −£35.5m
Extracted automatically from the company's results announcements; check the source before relying on a figure. Not investment advice.
Latest report: H1 26 (six months to 30 Jun 26), published 22 Sep 26 · read the results ↗
£m unless stated · newest first · italic = calculated (LTM, H2 = FY − H1) · hover a value for its source
| LTM Jun 26 | FY 25 | FY 24 | FY 23 | FY 22 | |
|---|---|---|---|---|---|
| Revenue | 4.8 | 3.5 | 3.8 | 2.7 | 13.3 |
| Operating profit | (76.7) | (74.8) | (106.5) | (117.6) | (168.4) |
| Share-based payments | 6.2 | 6.2 | 17.9 | 3.6 | 12.5 |
| Fair value gains / losses | – | 29.2 | (1.9) | 62.7 | (27.3) |
| Finance costs | – | (1.4) | (1.4) | (2.8) | (3.4) |
| Profit before tax | 3.8 | (84.2) | 18.6 | (29.0) | (79.0) |
| Tax | (3.2) | 0.6 | 3.1 | (24.6) | 47.4 |
| Net income (owners) | 1.1 | (83.3) | 41.9 | (52.8) | (42.9) |
| EPS basic | 0.8p | (34.2p) | 16.7p | (18.8p) | (14.9p) |
| EPS diluted | 0.1p | (34.2p) | 16.7p | (18.8p) | (14.9p) |
| H1 26 | vs H1 25 | H2 25 | H1 25 | H2 24 | H1 24 | H2 23 | |
|---|---|---|---|---|---|---|---|
| Revenue | 2.6 | +85% | 2.1 | 1.4 | 3.6 | 0.2 | 0.1 |
| Operating profit | (38.9) | n/m | (37.8) | (37.0) | (54.0) | (52.5) | (55.8) |
| Share-based payments | 3.6 | −2% | 2.6 | 3.7 | 14.2 | 3.7 | 2.5 |
| Fair value gains / losses | – | – | 26.4 | 2.8 | (4.9) | 3.1 | 56.4 |
| Finance costs | – | – | (0.7) | (0.7) | (0.5) | (0.8) | – |
| Profit before tax | 54.1 | n/m | (50.3) | (33.9) | 62.1 | (43.5) | (17.9) |
| Tax | (4.5) | n/m | 1.4 | (0.7) | (1.7) | 4.9 | (15.0) |
| Net income (owners) | 50.0 | n/m | (48.9) | (34.4) | 74.9 | (33.0) | (32.6) |
| EPS basic | 21.1p | – | (20.3p) | (13.8p) | 28.6p | (11.9p) | (11.7p) |
| EPS diluted | 20.4p | – | (20.3p) | (13.8p) | 28.6p | (11.9p) | (11.7p) |
| LTM Jun 26 | FY 25 | FY 24 | FY 23 | FY 22 | |
|---|---|---|---|---|---|
| Cash from operations | (62.2) | (64.6) | (105.1) | (85.2) | (152.2) |
| Interest paid | (5.5) | (3.4) | (1.0) | (1.4) | (2.9) |
| Tax paid | (0.1) | (4.2) | (29.7) | (0.1) | (17.6) |
| Capex (PP&E) | – | (0.0) | (0.0) | (0.1) | (1.9) |
| Capex (intangibles) | – | – | – | (0.1) | 0.0 |
| Lease principal paid | (2.6) | (2.7) | (2.7) | (2.7) | (3.4) |
| Share buybacks | – | (1.6) | (80.4) | 0.0 | (22.6) |
| Shares issued | – | 0.1 | 0.7 | 0.9 | 0.3 |
| H1 26 | vs H1 25 | H2 25 | H1 25 | H2 24 | H1 24 | H2 23 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | (33.0) | n/m | (29.2) | (35.5) | (41.9) | (63.2) | (32.4) |
| Interest paid | (2.7) | +300% | (2.8) | (0.7) | (0.5) | (0.5) | (0.5) |
| Tax paid | (0.0) | −100% | (0.1) | (4.1) | (17.6) | (12.0) | 0.0 |
| Capex (PP&E) | – | – | – | – | – | – | 0.0 |
| Lease principal paid | (1.3) | −8% | (1.3) | (1.4) | (1.4) | (1.3) | (1.3) |
| Lease interest paid | – | – | – | – | – | (0.5) | – |
| Share buybacks | – | – | 0.0 | (1.6) | (0.1) | (80.3) | 5.9 |
| Shares issued | – | – | (0.0) | 0.1 | (0.0) | 0.7 | 0.1 |
| Latest Jun 26 | FY 25 | FY 24 | FY 23 | FY 22 | |
|---|---|---|---|---|---|
| Other intangibles | 0.2 | 0.4 | 0.5 | 0.7 | 0.7 |
| Property, plant & equipment | 3.3 | 3.9 | 5.6 | 7.5 | 19.0 |
| Associates & JVs | – | 0.0 | 1.9 | 2.5 | 7.6 |
| Other investments | – | 161.4 | 152.5 | 249.6 | 208.9 |
| Trade receivables | 1.6 | 1.3 | 1.2 | 1.9 | 9.8 |
| Cash | 91.5 | 187.5 | 223.6 | 150.1 | 124.3 |
| Current assets | 190.4 | 226.5 | 307.8 | 272.7 | 320.3 |
| Total assets | 480.8 | 397.0 | 480.2 | 545.0 | 582.8 |
| Trade payables | 15.8 | 17.2 | 21.5 | 34.6 | 45.5 |
| Borrowings, current | 4.1 | 3.7 | 3.3 | 0.0 | 4.3 |
| Lease liabilities, current | 2.8 | 2.7 | 2.9 | 2.7 | 4.1 |
| Current liabilities | 41.4 | 34.4 | 33.0 | 40.3 | 80.4 |
| Borrowings, non-current | – | – | – | 0.0 | 8.5 |
| Lease liabilities, non-current | 6.9 | 8.2 | 11.7 | 14.3 | 20.0 |
| Total liabilities | 194.5 | 170.1 | 155.2 | 185.1 | 128.6 |
| Non-controlling interests | (5.1) | (4.8) | (5.4) | (4.6) | 4.5 |
| Total equity | 286.3 | 227.0 | 325.1 | 359.8 | 454.2 |
| Shares in issue | 257.9m | – | 257.9m | 289.5m | – |
| Treasury shares | 14.5m | – | 18.5m | 17.6m | – |
| H1 26 | H2 25 | H1 25 | H2 24 | H1 24 | H2 23 | |
|---|---|---|---|---|---|---|
| Other intangibles | 0.2 | 0.4 | 0.4 | 0.5 | 0.7 | 0.7 |
| Property, plant & equipment | 3.3 | 3.9 | 4.5 | 5.6 | 6.6 | 7.5 |
| Associates & JVs | – | 0.0 | – | 1.9 | – | 2.5 |
| Other investments | – | 161.4 | 139.8 | 152.5 | 23.0 | 249.6 |
| Trade receivables | 1.6 | 1.3 | 1.8 | 1.2 | 1.6 | 1.9 |
| Cash | 91.5 | 187.5 | 189.9 | 223.6 | 243.9 | 150.1 |
| Current assets | 190.4 | 226.5 | 251.0 | 307.8 | 402.4 | 272.7 |
| Total assets | 480.8 | 397.0 | 403.2 | 480.2 | 458.6 | 545.0 |
| Trade payables | 15.8 | 17.2 | 13.7 | 21.5 | 24.9 | 34.6 |
| Borrowings, current | 4.1 | 3.7 | 3.3 | 3.3 | – | 0.0 |
| Lease liabilities, current | 2.8 | 2.7 | 2.5 | 2.9 | 2.8 | 2.7 |
| Current liabilities | 41.4 | 34.4 | 29.6 | 33.0 | 109.4 | 40.3 |
| Borrowings, non-current | – | – | – | – | – | 0.0 |
| Lease liabilities, non-current | 6.9 | 8.2 | 9.4 | 11.7 | 13.0 | 14.3 |
| Total liabilities | 194.5 | 170.1 | 134.3 | 155.2 | 216.5 | 185.1 |
| Non-controlling interests | (5.1) | (4.8) | (5.1) | (5.4) | (7.6) | (4.6) |
| Total equity | 286.3 | 227.0 | 269.0 | 325.1 | 242.1 | 359.8 |
| Shares in issue | 257.9m | – | – | 257.9m | 257.9m | 289.5m |
| Treasury shares | 14.5m | – | – | 18.5m | 18.5m | 17.6m |
Line items extracted automatically from each results announcement; when a later report restates a period, the later figure is shown. LTM and H2 are calculated from reported periods. Check the source before relying on a figure.
Company filings. Not investment advice.